SynthesisBMC pulmonary medicine2025
Outcomes of lung transplantation for end stage lung disease with connective tissue disease: a systematic review and meta-analysis.
Synthesis in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundLung transplantation is the most important treatment for end-stage lung disease. However, the clinical outcomes of lung transplantation in patients with connective tissue disease(CTD) complicated with end-stage pulmonary complications are unclear. Consequently, we performed a systematic review and meta-analysis to compare the survival rates and incidences of adverse events between patients with and without CTD who underwent lung transplantation for end-stage lung disease.
methodsWe searched the PubMed, Embase, Web of Science, Cochrane, Wanfang, VIP, CNKI, and CBM databases from their inception until October 18, 2023, for eligible studies. A meta-analysis of each study was performed using State14.0 with a 95% confidence interval (CI). A randomized or fixed-effect model was applied according to the heterogeneity test. The systematic review was registered in PROSPERO (CRD42023483687).
resultsOur final analysis included 12 publications on 369 patients with CTD and 2,165 without, all of whom underwent lung transplantation. The survival at 1 month (OR = 2.20, 95% CI: 0.75-6.47, P = 0.485), 6 months (OR = 0.61, 95% CI: 0.33-1.14, P = 0.099), 1 year (OR = 1.05, 95% CI: 0.66-1.66, P = 0.982), 2 years (OR = 0.50, 95% CI: 0.23-1.06, P = 0.096), 3 years(OR = 1.11, 95% CI: 0.70-1.78, P = 0.703) and 5 years (OR = 2.08, 95% CI: 1.11-3.91, P = 0.027), grade 3 primary graft dysfunction (PGD) incidence (OR = 1.33, 95% CI: 0.68-2.60, P = 0.184), rejection events incidence (OR = 1.19, 95% CI: 0.61-2.32, P = 0.607) and intensive care unit (ICU) LOS (SMD = 0.54, 95% CI:-0.26-1.34, P = 0.187) were similar between the two groups. Patients with CTD had a greater risk of PGD incidence (OR = 2.91, 95% CI: 1.43-5.95, P = 0.003), a longer post-transplant hospital length of stay (LOS) (SMD = 0.52, 95% CI: 0.09-0.96, P = 0.009) and post-transplant time to extubation (SMD = 0.68, 95% CI: 0.12-1.25, P = 0.023).
conclusionsThe survival rate and the incidence of grade 3 PGD in CTD patients after lung transplantation are comparable to those of other patients undergoing lung transplantation for end-stage lung disease. Thus, Lung transplantation should be a strongly considered therapeutic option for patients with CTD who are suffering from end-stage lung disease. Nevertheless, when selecting patients with CTD for lung transplantation, it is crucial to focus on enhancing perioperative management to reduce the burden of hospitalization post-transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.